Segment, Geographic and Other Revenue Information (Tables)


The following provides selected information by reportable segment:
	Three Months Ended
	Total Revenues				Earnings(a)				Depreciation and Amortization(b)
(MILLIONS)	March 29, 2026		March 30, 2025		March 29, 2026		March 30, 2025		March 29, 2026		March 30, 2025
Reportable Segment:
Biopharma(c)	$	14,161	$	13,441	$	6,838	$	7,069	$	348	$	331
Other business activities(d)	289		273		(1,668)		(1,384)		78		74
Reconciling Items:
Amortization of intangible assets					(1,183)		(1,211)		1,183		1,211
Acquisition-related items					(504)		(282)		—		(1)
Certain significant items(e)					(312)		(1,407)		3		4
	$	14,451	$	13,715	$	3,170	$	2,785	$	1,613	$	1,618

(a)Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.

(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

(c)Biopharma’s earnings include dividend income from our investment in ViiV of $82 million in the first quarter of 2026 and $39 million in the first quarter of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first quarter of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.

(d)Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.

(e)Earnings in the first quarter of 2025 included, among other items restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $666 million (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.


The following provides Biopharma reportable segment information regularly provided to the CODM:
	Three Months Ended
(MILLIONS)	March 29, 2026		March 30, 2025
Biopharma reportable segment:
Biopharma total revenues	$	14,161	$	13,441
Less:
Cost of sales	3,034		2,314
Selling, informational and administrative expenses	2,131		2,186
Research and development expenses	2,137		1,941
Acquired in-process research and development expenses	137		9
Other (income)/deductions––net	(116)		(78)
Biopharma earnings	$	6,838	$	7,069


The following summarizes revenues by geographic area:
	Three Months Ended
(MILLIONS)	March 29, 2026		March 30, 2025
United States	$	8,731	$	8,374
International:
Developed Markets	3,426		3,178
Emerging Markets	2,293		2,163
Total revenues	$	14,451	$	13,715

The following provides detailed revenue information for several of our major products:


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 29, 2026		March 30, 2025
TOTAL REVENUES		$	14,451	$	13,715
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a)		$	14,161	$	13,441
Primary Care		$	5,542	$	5,692
Eliquis(b)	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	2,166		1,923
Prevnar family	Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae	1,690		1,660
Nurtec ODT/Vydura	Acute treatment of migraine and prevention of episodic migraine	353		248
Comirnaty	Active immunization to prevent COVID-19	232		565
Paxlovid	COVID-19 in certain high-risk patients	186		491
Abrysvo	Active immunization to prevent RSV infection	180		131
FSME-IMMUN/TicoVac	Active immunization to prevent tick-borne encephalitis disease	81		63
All other Primary Care	Various	654		609
Oncology		$	3,826	$	3,494
Ibrance	HR-positive/HER2-negative metastatic breast cancer	1,008		977
Padcev	Locally advanced or metastatic urothelial cancer and cisplatin-ineligible/decline muscle invasive bladder cancer (MIBC)	591		426
Xtandi(c)	mCRPC, nmCRPC, mCSPC, nmCSPC	444		458
Lorbrena	ALK-positive metastatic NSCLC	305		222
Inlyta	Advanced renal cell carcinoma	214		219
Adcetris(d)	Certain lymphomas including classical Hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma	190		218
Braftovi/Mektovi	Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(e) (after prior therapy) or cetuximab and fluorouracil-based chemotherapy	174		136
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	129		151
Tukysa	Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer	122		102
Orgovyx(f)	Advanced prostate cancer	109		76
Elrexfio	Relapsed or refractory multiple myeloma	80		60
Talzenna	Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC	50		40
Tivdak	Recurrent or mCC with disease progression on or after chemotherapy	33		33
All other Oncology	Various	376		377
Specialty Care		$	2,939	$	2,616
Vyndaqel family	ATTR-CM and polyneuropathy	1,602		1,486
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis	180		128
Zavicefta (Outside the U.S. and Canada)	Bacterial infections	150		135
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	138		140
Octagam	Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults	122		88
Genotropin	Replacement of human growth hormone	93		95
Cibinqo	Atopic dermatitis	76		58
All other Specialty Care	Various	579		486
Hospital and Biosimilars(a)		$	1,854	$	1,639
Oncology biosimilars(g)	Various	409		264
Sulperazon (Outside the U.S. and Canada)	Bacterial infections	199		164
Inflectra	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	182		153
Zithromax	Bacterial infections	112		158
All other Hospital and Biosimilars	Various	953		901
PFIZER CENTREONE(h)		$	289	$	273


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 29, 2026		March 30, 2025
BIOPHARMA(a)		$	14,161	$	13,441
PFIZER U.S. COMMERCIAL DIVISION		7,686		7,572
PFIZER INTERNATIONAL COMMERCIAL DIVISION		5,233		4,849
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(i)		1,242		1,020

Total Alliance revenues included above		$	2,339	$	2,113
Total Royalty revenues included above		$	396	$	308

(a)In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation.

(b)Reflects alliance revenues and royalty revenues.

(c)Primarily reflects alliance revenues and royalty revenues.

(d)Reflects product revenues and royalty revenues.

(e)Erbitux® is a registered trademark of ImClone LLC.

(f)Reflects alliance revenues.

(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.

(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. We reclassified prior period amounts to conform to the current period presentation.

(i)See Note 13A above.